Quick Answer
INTEGRATED BIOPHARMA INC reported Total Assets of $24.90 million for the year ending 2025.
- INTEGRATED BIOPHARMA INC showed a decrease of -5.0% in Total Assets from 2024 to 2025.
- This data is from INTEGRATED BIOPHARMA INC's annual report (Form 10-K), filed with the SEC on September 23, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2011: $11.53 million | Q1 2012: $10.75 million | Q3 2012: $12.17 million | Q4 2012: $13.59 million | Q1 2013: $12.73 million | Q3 2013: $12.57 million | Q1 2014: $10.32 million | Q3 2014: $13.14 million | Q4 2014: $13.66 million | Q1 2015: $12.42 million | Q2 2015: $11.62 million | Q3 2015: $12.08 million | Q4 2015: $14.22 million | Q1 2016: $14.11 million | Q3 2016: $14.65 million | Q4 2016: $15.00 million | Q1 2017: $13.61 million | Q3 2017: $13.38 million | Q4 2017: $15.65 million | Q1 2018: $14.62 million | Q3 2018: $19.72 million | Q4 2018: $22.58 million | Q3 2019: $19.64 million | Q4 2019: $19.97 million | Q1 2020: $20.65 million | Q3 2020: $24.63 million | Q4 2020: $25.26 million | Q1 2021: $26.13 million | Q3 2021: $24.34 million | Q4 2021: $27.07 million | Q1 2022: $27.70 million | Q3 2022: $26.36 million | Q4 2022: $26.05 million | Q1 2023: $26.88 million | Q2 2023: $26.21 million | Q3 2023: $26.64 million | Q4 2023: $25.72 million | Q1 2024: $26.94 million | Q3 2024: $26.18 million | Q4 2024: $25.66 million | Q1 2025: $25.66 million | Q2 2025: $24.90 million | Q3 2025: $25.54 million | Q4 2025: $23.55 million.
- Over the full 15 years of available data (2011 to 2025), INTEGRATED BIOPHARMA INC's Total Assets has grown by 82.4%.
- Historical annual values: Fiscal year 2025: $24.90 million | Fiscal year 2024: $26.21 million | Fiscal year 2023: $25.43 million | Fiscal year 2022: $25.25 million | Fiscal year 2021: $25.44 million | Fiscal year 2020: $22.94 million | Fiscal year 2019: $19.79 million | Fiscal year 2018: $14.57 million | Fiscal year 2017: $15.20 million | Fiscal year 2016: $13.95 million | Fiscal year 2015: $11.62 million | Fiscal year 2014: $11.58 million | Fiscal year 2013: $12.61 million | Fiscal year 2012: $11.88 million | Fiscal year 2011: $13.65 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: